Qyuns Therapeutics Co., Ltd. Class H 2509
HKEX · Hong Kong SAR China · Health Technology
HKD 17.00+0.05 (+0.29%)
Market closed· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
The startups are part of a surge of young companies equipped with advanced drug prospects and quickly pivoting to the public markets.
Amidst geopolitical tensions and rising energy prices impacting global markets, Asian equities have experienced fluctuations as investors navigate these uncertainties. In this environment, identifying stocks that may be undervalued involves assessing companies with strong fundamentals and growth potential that are currently priced below their intrinsic value.
In the current landscape, Asian markets are navigating through heightened geopolitical tensions and fluctuating energy prices, contributing to a complex economic environment. Amidst these challenges, identifying undervalued stocks can offer potential opportunities for investors seeking value in a turbulent market. Recognizing stocks trading below their intrinsic value may provide an edge in capitalizing on long-term growth prospects despite short-term uncertainties.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.